Mereo BioPharma Group (MREO) EBIAT: 2023-2025
Historic EBIAT for Mereo BioPharma Group (MREO) over the last 3 years, with Sep 2025 value amounting to -$7.0 million.
- Mereo BioPharma Group's EBIAT rose 53.18% to -$7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$41.6 million, marking a year-over-year increase of 8.26%. This contributed to the annual value of -$43.3 million for FY2024, which is 46.79% down from last year.
- According to the latest figures from Q3 2025, Mereo BioPharma Group's EBIAT is -$7.0 million, which was up 51.94% from -$14.6 million recorded in Q2 2025.
- In the past 5 years, Mereo BioPharma Group's EBIAT registered a high of -$1.8 million during Q2 2023, and its lowest value of -$15.0 million during Q3 2024.
- Over the past 3 years, Mereo BioPharma Group's median EBIAT value was -$9.1 million (recorded in 2023), while the average stood at -$9.7 million.
- Per our database at Business Quant, Mereo BioPharma Group's EBIAT plummeted by 599.89% in 2024 and then spiked by 53.18% in 2025.
- Over the past 3 years, Mereo BioPharma Group's EBIAT (Quarterly) stood at -$9.1 million in 2023, then rose by 22.65% to -$7.0 million in 2024, then surged by 53.18% to -$7.0 million in 2025.
- Its EBIAT stands at -$7.0 million for Q3 2025, versus -$14.6 million for Q2 2025 and -$12.9 million for Q1 2025.